使用复方制剂预防心血管疾病。 - Suppr

Suppr

超能文献

Use of polypills for CVD prevention.

作者信息

Huynh Karina

机构信息

Nature Reviews Cardiology, .

出版信息

Nat Rev Cardiol. 2019 Nov;16(11):649. doi: 10.1038/s41569-019-0267-1.

DOI:10.1038/s41569-019-0267-1

PMID:31492914

Abstract

摘要

相似文献

Use of polypills for CVD prevention.

Nat Rev Cardiol. 2019 Nov;16(11):649. doi: 10.1038/s41569-019-0267-1.

Polypills for the prevention of Cardiovascular diseases.

Expert Opin Investig Drugs. 2016 Nov;25(11):1255-1264. doi: 10.1080/13543784.2016.1236912. Epub 2016 Sep 22.

Polypills: essential medicines for cardiovascular disease secondary prevention?

J Am Coll Cardiol. 2014 Apr 15;63(14):1368-70. doi: 10.1016/j.jacc.2013.08.1665. Epub 2014 Feb 19.

Uses of polypills for cardiovascular disease and evidence to date.

Lancet. 2017 Mar 11;389(10073):1055-1065. doi: 10.1016/S0140-6736(17)30553-6.

Putting polypills into practice: challenges and lessons learned.

Lancet. 2017 Mar 11;389(10073):1066-1074. doi: 10.1016/S0140-6736(17)30558-5.

Polypills for primary prevention of cardiovascular disease.

Nat Rev Cardiol. 2019 Oct;16(10):602-611. doi: 10.1038/s41569-019-0209-y.

Polypills for the secondary prevention of MACE.

Nat Rev Cardiol. 2022 Nov;19(11):720. doi: 10.1038/s41569-022-00786-7.

Benefit of polypills in a low socioeconomic community in the USA.

Nat Rev Cardiol. 2019 Dec;16(12):701. doi: 10.1038/s41569-019-0295-x.

Progressing polypills beyond concepts to outcomes.

Lancet. 2019 Aug 24;394(10199):617-619. doi: 10.1016/S0140-6736(19)31953-1.

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.

Curr Cardiol Rep. 2017 May;19(5):45. doi: 10.1007/s11886-017-0853-y.

本文引用的文献

Polypills for primary prevention of cardiovascular disease.

Nat Rev Cardiol. 2019 Oct;16(10):602-611. doi: 10.1038/s41569-019-0209-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Use of polypills for CVD prevention.

Nat Rev Cardiol. 2019 Nov;16(11):649. doi: 10.1038/s41569-019-0267-1.

Polypills for the prevention of Cardiovascular diseases.

Expert Opin Investig Drugs. 2016 Nov;25(11):1255-1264. doi: 10.1080/13543784.2016.1236912. Epub 2016 Sep 22.

Polypills: essential medicines for cardiovascular disease secondary prevention?

J Am Coll Cardiol. 2014 Apr 15;63(14):1368-70. doi: 10.1016/j.jacc.2013.08.1665. Epub 2014 Feb 19.

Uses of polypills for cardiovascular disease and evidence to date.

Lancet. 2017 Mar 11;389(10073):1055-1065. doi: 10.1016/S0140-6736(17)30553-6.

Putting polypills into practice: challenges and lessons learned.

Lancet. 2017 Mar 11;389(10073):1066-1074. doi: 10.1016/S0140-6736(17)30558-5.

Polypills for primary prevention of cardiovascular disease.

Nat Rev Cardiol. 2019 Oct;16(10):602-611. doi: 10.1038/s41569-019-0209-y.

Polypills for the secondary prevention of MACE.

Nat Rev Cardiol. 2022 Nov;19(11):720. doi: 10.1038/s41569-022-00786-7.

Benefit of polypills in a low socioeconomic community in the USA.

Nat Rev Cardiol. 2019 Dec;16(12):701. doi: 10.1038/s41569-019-0295-x.

Progressing polypills beyond concepts to outcomes.

Lancet. 2019 Aug 24;394(10199):617-619. doi: 10.1016/S0140-6736(19)31953-1.

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.

Curr Cardiol Rep. 2017 May;19(5):45. doi: 10.1007/s11886-017-0853-y.

本文引用的文献

Polypills for primary prevention of cardiovascular disease.

Nat Rev Cardiol. 2019 Oct;16(10):602-611. doi: 10.1038/s41569-019-0209-y.